TGTX
TG Therapeutics, Inc.
Biotechnology · Healthcare · United States
47.94
close · 2026-08-13
value
32
cheaper than peers32
quality
84
stronger fundamentals84
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 16.17× | 60 |
| price to sales | 10.09× | 56 |
| price to book | 11.65× | 21 |
| EV to EBITDA | 50.90× | 19 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 112.6% | 98 |
| operating margin | 17.0% | 80 |
| revenue growth | 69.6% | 70 |
| debt to equity | 129.2% | 20 |
4 of 4 measures available
Facts
| market cap | $7B |
| free cash flow | -$30.2M |
| employees | 399 |
| first trade | 2010-05-03 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-03 |